Glioma-derived mutations in IDH: From mechanism to potential therapy

Biochemical and Biophysical Research Communications

Volumn 397, Issue 2, 2010, Pages 127-130

  Fu, Yuejun ^a   Huang, Rui ^a   Du, Jun ^a   Yang, Renjia ^a   An, Na ^a   Liang, Aihua ^a  

^a SHANXI UNIVERSITY   (China)

Author keywords

Gliomas; IDH2; Isocitrate dehydrogenase 1 (IDH1); Mutation

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN;

GENETIC GAIN; GLIOMA; HUMAN; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; BRAIN TUMOR; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; RADIATION DOSE;

BRAIN NEOPLASMS; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; MUTATION; PROTEIN CONFORMATION; RADIATION TOLERANCE;

EID: 77955508065     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.115     Document Type: Short Survey

References (46)

1. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvet, B.W. Scheithauer, P. Kleihues, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol. 114 (2007) 97-109.
2. P.C. Burger, B.W. Scheithauer, W. Paulus, Pilocytic astrocytoma, in: P. Kleihues, W.K. Cavenee (Eds.), Pathology and Genetics of Tumours of the Nervous System, IARC Press, Lyon, 2000, pp. 45-51.
3. R. Stupp, W.P. Mason, M.J. Van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med. 352 (2005) 987-996.
4. P.Y. Wen, S. Kesari, Malignant gliomas in adults, N. Engl. J. Med. 359 (2008) 492-507.
5. L.T. Yin, Y.J. Fu, Q.L. Xu, J. Yang, Z.L. Liu, A.H. Liang, X.J. Fan, C.G. Xu, Potential biochemical therapy of glioma cancer, Biochem. Biophys. Res. Commun. 362 (2007) 225-229.
6. B. Grobben, P.P. De Deyn, H. Slegers, Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion, Cell Tissue Res. 310 (2002) 257-270.
7. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, P. Angenendt, P. Mankoo, H. Carter, I.M. Siu, G.L. Gallia, A. Olivi, R. McLendon, B.A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D.A. Busam, H. Tekleab, L.A. Diaz Jr., J. Hartigan, D.R. Smith, R.L. Strausberg, S.K. Marie, S.M. Shinjo, H. Yan, G.J. Riggins, D.D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V.E. Velculescu, K.W. Kinzler, An integrated genomic analysis of human glioblastoma multiforme, Science 321 (2008) 1807-1812.
8. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, A. von Deimling, Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathol. 116 (2008) 597-602.
9. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, D.D. Bigner, IDH1 and IDH2 mutations in gliomas, N. Engl. J. Med. 360 (2009) 765-773.
10. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.L. Guan, Y. Xiong, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science 324 (2009) 261-265.
11. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, K.M. Marks, R.M. Prins, P.S. Ward, K.E. Yen, L.M. Liau, J.D. Rabinowitz, L.C. Cantley, C.B. Thompson, M.G. Vander Heiden, S.M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature 462 (2009) 739-744.
12. F.E. Bleeker, N.A. Atai, S. Lamba, A. Jonker, D. Rijkeboer, K.S. Bosch, W. Tigchelaar, D. Troost, W.P. Vandertop, A. Bardelli, C.J. Van Noorden, The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma, Acta Neuropathol. 119 (2010) 487-494.
13. Y. Kato, G. Jin, C.T. Kuan, R.E. McLendon, H. Yan, D.D. Bigner, A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation, Biochem. Biophys. Res. Commun. 390 (2009) 547-551.
14. D. Capper, H. Zentgraf, J. Balss, C. Hartmann, A. von Deimling, Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathol. 118 (2009) 599-601.
15. T. Watanabe, S. Nobusawa, P. Kleihues, H. Ohgaki, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, Am. J. Pathol. 174 (2009) 1149-1153.
16. K. Ichimura, D.M. Pearson, S. Kocialkowski, L.M. Backlund, R. Chan, D.T. Jones, V.P. Collins, IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas, Neuro. Oncol. 11 (2009) 341-347.
17. B.V. Geisbrecht, S.J. Gould, The human PICD gene encodes a cytoplasmic and peroxisomal NADP (+)-dependent isocitrate dehydrogenase, J. Biol. Chem. 274 (1999) 30527-30533.
18. E. Margittai, G. Bánhegyi, Isocitrate dehydrogenase: A NADPH-generating enzyme in the lumen of the endoplasmic reticulum, Arch. Biochem. Biophys. 471 (2008) 184-190.
19. X. Xu, J. Zhao, Z. Xu, B. Peng, Q. Huang, E. Arnold, J. Ding, Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self regulatory mechanism of activity, J. Biol. Chem. 279 (2004) 33946-33957.
20. S.M. Lee, H.J. Koh, D.C. Park, B.J. Song, T.L. Huh, J.W. Park, Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells, Free Radic. Biol. Med. 32 (2002) 1185-1196.
21. S.Y. Kim, S.M. Lee, J.K. Tak, K.S. Choi, T.K. Kwon, J.W. Park, Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase, Mol. Cell. Biochem. 302 (2007) 27-34.
22. B.S. Winkler, N. DeSantis, F. Solomon, Multiple NADPH-producing pathways control glutathione (GSH) content in retina, Exp. Eye Res. 43 (1986) 829-847.
23. W. Ying, NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences, Antioxid. Redox Signal. 10 (2008) 179-206.
24. F.E. Bleeker, S. Lamba, S. Leenstra, D. Troost, T. Hulsebos, W.P. Vandertop, M. Frattini, F. Molinari, M. Knowles, A. Cerrato, M. Rodolfo, A. Scarpa, L. Felicioni, F. Buttitta, S. Malatesta, A. Marchetti, A. Bardelli, IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors, Hum. Mutat. 30 (2009) 7-11.
25. C. Hartmann, J. Meyer, J. Balss, D. Capper, W. Mueller, A. Christians, J. Felsberg, M. Wolter, C. Mawrin, W. Wick, M. Weller, C. Herold-Mende, A. Unterberg, J.W. Jeuken, P. Wesseling, G. Reifenberger, A. von Deimling, Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas, Acta Neuropathol. 118 (2009) 469-474.
26. M.R. Kang, M.S. Kim, J.E. Oh, Y.R. Kim, S.Y. Song, S.I. Seo, J.Y. Lee, N.J. Yoo, S.H. Lee, Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers, Int. J. Cancer 125 (2009) 353-355.
27. E.R. Mardis, L. Ding, D.J. Dooling, D.E. Larson, M.D. McLellan, K. Chen, D.C. Koboldt, R.S. Fulton, K.D. Delehaunty, S.D. McGrath, L.A. Fulton, D.P. Locke, V.J. Magrini, R.M. Abbott, T.L. Vickery, J.S. Reed, J.S. Robinson, T. Wylie, S.M. Smith, L. Carmichael, J.M. Eldred, C.C. Harris, J. Walker, J.B. Peck, F. Du, A.F. Dukes, G.E. Sanderson, A.M. Brummett, E. Clark, J.F. McMichael, R.J. Meyer, J.K. Schindler, C.S. Pohl, J.W. Wallis, X. Shi, L. Lin, H. Schmidt, Y. Tang, C. Haipek, M.E. Wiechert, J.V. Ivy, J. Kalicki, G. Elliott, R.E. Ries, J.E. Payton, P. Westervelt, M.H. Tomasson, M.A. Watson, J. Baty, S. Heath, W.D. Shannon, R. Nagarajan, D.C. Link, M.J. Walter, T.A. Graubert, J.F. DiPersio, R.K. Wilson, T.J. Ley, Recurring mutations found by sequencing an acute myeloid leukemia genome, N. Engl. J. Med. 361 (2009) 1058-1066.
28. S.W. Park, N.G. Chung, J.Y. Han, H.S. Eom, J.Y. Lee, N.J. Yoo, S.H. Lee, Absence of IDH2 codon 172 mutation in common human cancers, Int. J. Cancer. 125 (2009) 2485-2486.
29. A.K. Murugan, E. Bojdani, M. Xing, Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer, Biochem. Biophys. Res. Commun. 393 (2010) 555-559.
30. P.J. Pollard, P.J. Ratcliffe, Cancer: puzzling patterns of predisposition, Science 324 (2009) 192-194.
31. C.B. Thompson, Metabolic enzymes as oncogenes or tumor suppressors, N. Engl. J. Med. 360 (2009) 813-815.
32. J.M. Hughes, A.J. Groot, P. van der Groep, R. Sersansie, M. Vooijs, P.J. van Diest, C.J. Van Noorden, R.O. Schlingemann, I. Klaassen, Active HIF-1 in the normal human retina, J. Histochem. Cytochem. 58 (2010) 247-254.
33. O.C. Ingebretsen, Mechanism of the inhibitory effect of glyoxylate plus oxaloacetate and oxalomalate on the NADP-specific isocitrate dehydrogenase, Biochim. Biophys. Acta 452 (1976) 302-309.
34. M. Duran, J.P. Kamerling, H.D. Bakker, A.H. van Gennip, S.K. Wadman, L-2-Hydroxyglutaric aciduria: an inborn error of metabolism?, J Inherit. Metab. Dis. 3 (1980) 109-112.
35. R.A. Chalmers, A.M. Lawson, R.W. Watts, A.S. Tavill, J.P. Kamerling, E. Hey, D. Ogilvie, D-2-hydroxyglutaric aciduria: case report and biochemical studies, J. Inherit. Metab. Dis. 3 (1980) 11-15.
36. E.A. Struys, G.S. Salomons, Y. Achouri, E. Van Schaftingen, S. Grosso, W.J. Craigen, N.M. Verhoeven, C. Jakobs, Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria, Am. J. Hum. Genet. 76 (2005) 358-360.
37. S. Kölker, E. Mayatepek, G.F. Hoffmann, White matter disease in cerebral organic acid disorders: clinical implications and suggested pathomechanisms, Neuropediatrics 33 (2002) 223-225.
38. M. Wajner, A. Latini, A.T. Wyse, C.S. Dutra-Filho, The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies, J. Inherit. Metab. Dis. 27 (2004) 427-448.
39. M. Aghili, F. Zahedi, E. Rafiee, Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review, J. Neurooncol. 91 (2009) 233-236.
40. S. Kölker, V. Pawlak, B. Ahlemeyer, J.G. Okun, F. Hörster, E. Mayatepek, J. Krieglstein, G.F. Hoffmann, G. Köhr, NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria, Eur. J. Neurosci. 16 (2002) 21-28.
41. A. Latini, K. Scussiato, R.B. Rosa, S. Llesuy, A. Belló-Klein, C.S. Dutra-Filho, M. Wajner, D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats, Eur. J. Neurosci. 17 (2003) 2017-2022.
42. S. Gross, R.A. Cairns, M.D. Minden, E.M. Driggers, M.A. Bittinger, H.G. Jang, M. Sasaki, S. Jin, D.P. Schenkein, S.M. Su, L. Dang, V.R. Fantin, T.W. Mak, Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations, J. Exp. Med. 207 (2010) 339-344.
43. S. Nobusawa, T. Watanabe, P. Kleihues, H. Ohgaki, IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas, Clin. Cancer Res. 15 (2009) 6002-6007.
44. Y. Sonoda, T. Kumabe, T. Nakamura, R. Saito, M. Kanamori, Y. Yamashita, H. Suzuki, T. Tominaga, Analysis of IDH1 and IDH2 mutations in Japanese glioma patients, Cancer Sci. 100 (2009) 1996-1998.
45. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, J.Y. Delattre, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J. Clin. Oncol. 27 (2009) 4150-4154.
46. M. Weller, J. Felsberg, C. Hartmann, H. Berger, J.P. Steinbach, J. Schramm, M. Westphal, G. Schackert, M. Simon, J.C. Tonn, O. Heese, D. Krex, G. Nikkhah, T. Pietsch, O. Wiestler, G. Reifenberger, A. von Deimling, M. Loeffler, Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network, J. Clin. Oncol. 27 (2009) 5743-5750.